Low-dose chemotherapy remodels hepatic immune landscape and potentiates anti-tumor response to immune checkpoint blockade in cholangiocarcinoma - PubMed
3 hours ago
- #immunotherapy
- #chemotherapy
- #cholangiocarcinoma
- Low-dose gemcitabine/cisplatin (LDGC) combined with anti-PD-L1 improves tumor immune microenvironment (TIME) in intrahepatic cholangiocarcinoma (ICC).
- LDGC reduces immunosuppressive SPP1+ tumor-associated macrophages (TAMs) and enhances CD8+ T cell infiltration and cytotoxicity.
- LDGC reprograms STAT1 and STAT3 pathways in TAMs, weakening the SPP1-VLA-4 signaling axis and boosting T cell response.
- Combination therapy shows superior response and tolerance in ICC patients compared to standard treatments.
- Study suggests LDGC with anti-PD-L1 as a rational regimen for ICC by remodeling the immunosuppressive microenvironment.